Correction: Quality Assurance Measurements for Range in Clinical and FLASH Proton Beam Therapy Utilizing the Range Calorimeter - Top-Institutions - MDSpire

Correction: Quality Assurance Measurements for Range in Clinical and FLASH Proton Beam Therapy Utilizing the Range Calorimeter

  • By

  • Saad Shaikh

  • Sonia Escribano-Rodriguez

  • Raffaella Radogna

  • Ruben Saakyan

  • Sam Manger

  • Nicholas Henthorn

  • John-William Warmenhoven

  • Michael Taylor

  • Simon Jolly

  • April 24, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The Christie NHS Foundation Trust
    The Christie NHS Foundation Trust

    Manchester, United Kingdom

    Key Differentiators

    • Proton Beam Therapy
    • Radiation Oncology
    • Medical Physics

  • #2

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Radiation Oncology
    • Proton Therapy
    • Medical Physics

  • #3

    Paul Scherrer Institute
    Paul Scherrer Institute

    Villigen, Switzerland

    Key Differentiators

    • Medical Physics
    • Proton Therapy
    • Radiation Oncology

  • #4

    University of Texas MD Anderson Cancer Center
    University of Texas MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Radiation Oncology
    • Proton Therapy
    • Medical Physics

  • #5

    Institut Curie
    Institut Curie

    Paris, France

    Key Differentiators

    • Radiation Oncology
    • Proton Therapy
    • Medical Physics

Original Source(s)

Correction: Quality Assurance Measurements for Range in Clinical and FLASH Proton Beam Therapy Utilizing the Range Calorimeter

  • by Saad Shaikh, Sonia Escribano-Rodriguez, Raffaella Radogna, Ruben Saakyan, Sam Manger, Nicholas Henthorn, John-William Warmenhoven, Michael Taylor, Simon Jolly

  • April 24, 2026

Related Content

MRI perfusion in evaluating ovarian masses: diagnostic performance of wash out rate

Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases

Impact of the clonal architecture and probable biallelic inactivation of TET2 mutations in myelodysplastic neoplasms